GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satsuma Pharmaceuticals Inc (NAS:STSA) » Definitions » Current Ratio

Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Current Ratio : 7.44 (As of Mar. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Satsuma Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Satsuma Pharmaceuticals's current ratio for the quarter that ended in Mar. 2023 was 7.44.

Satsuma Pharmaceuticals has a current ratio of 7.44. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Satsuma Pharmaceuticals's Current Ratio or its related term are showing as below:

STSA' s Current Ratio Range Over the Past 10 Years
Min: 1.13   Med: 12.27   Max: 25.5
Current: 7.44

During the past 6 years, Satsuma Pharmaceuticals's highest Current Ratio was 25.50. The lowest was 1.13. And the median was 12.27.

STSA's Current Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.71 vs STSA: 7.44

Satsuma Pharmaceuticals Current Ratio Historical Data

The historical data trend for Satsuma Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satsuma Pharmaceuticals Current Ratio Chart

Satsuma Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Ratio
Get a 7-Day Free Trial 2.75 14.40 9.17 11.76 6.75

Satsuma Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.77 9.18 10.15 6.75 7.44

Competitive Comparison of Satsuma Pharmaceuticals's Current Ratio

For the Biotechnology subindustry, Satsuma Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Satsuma Pharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Satsuma Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Satsuma Pharmaceuticals's Current Ratio falls into.



Satsuma Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Satsuma Pharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=54.809/8.115
=6.75

Satsuma Pharmaceuticals's Current Ratio for the quarter that ended in Mar. 2023 is calculated as

Current Ratio (Q: Mar. 2023 )=Total Current Assets (Q: Mar. 2023 )/Total Current Liabilities (Q: Mar. 2023 )
=43.375/5.831
=7.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Satsuma Pharmaceuticals  (NAS:STSA) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Satsuma Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Satsuma Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
400 Oyster Point Boulevard, Suite 221, South San Francisco, CA, USA, 94080
Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.
Executives
Mutya Harsch director C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Shin Nippon Biomedical Laboratories, Ltd. 10 percent owner 2438 MIYANOURA-MACHI, KAGOSHIMA CITY, KAGOSHIMA M0 891-1394
Thomas P Soloway director C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Ken Takanashi director, 10 percent owner C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Detlef Albrecht officer: Chief Medical Officer SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Thomas P. O'neil officer: Chief Financial Officer SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Rajeev M. Shah director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
John A Kollins director, officer: President and CEO SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080

Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Headlines

From GuruFocus